Literature DB >> 25297011

Idalopirdine for Alzheimer's disease: written in the stars.

Lon S Schneider1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25297011     DOI： 10.1016/S1474-4422(14)70232-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  3 in total

1.  A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.

Authors:  Terence Fullerton; Brendon Binneman; William David; Marielle Delnomdedieu; James Kupiec; Peter Lockwood; Jessica Mancuso; Jeffrey Miceli; Joanne Bell
Journal:  Alzheimers Res Ther       Date:  2018-04-05       Impact factor: 6.982

Review 2.  G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits.

Authors:  Shofiul Azam; Md Ezazul Haque; Md Jakaria; Song-Hee Jo; In-Su Kim; Dong-Kug Choi
Journal:  Cells       Date:  2020-02-23       Impact factor: 6.600

Review 3.  5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress.

Authors:  Megan Andrews; Babak Tousi; Marwan N Sabbagh
Journal:  Neurol Ther       Date:  2018-05-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.